Project Grant R01HL176920
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to elucidate the complex relationship between obstructive sleep apnea (OSA) and cardiovascular disease (CVD). The $1,296,660 award supports a 24-month research project that will employ a "bed to bench" approach integrating clinical, computational, and in vitro techniques. Key objectives include developing and validating a mathematical model to quantify...
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,415,112 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Nebraska Medical Center (UNMC) to evaluate a telehealth-delivered adaptive intervention for improving continuous positive airway pressure (CPAP) therapy adherence and health outcomes in adults with obstructive sleep apnea (OSA). The project aims to: 1) compare effects of motivational enhancement, device support, and...
- This $764,853 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Yale University supports research to understand the role of arousal threshold (ARTH) as a determinant of adherence and outcomes for continuous positive airway pressure (CPAP) therapy in obstructive sleep apnea (OSA). The research aims to validate ARTH as a biomarker to guide precision OSA therapy, as poor adherence and inconsistent impacts on neurocognitive and...
- This federal Project Grant award of $115,125.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the interaction between obstructive sleep apnea (OSA) and HIV infection on ventricular repolarization abnormalities. The research will be conducted by the University of Miami from February 1, 2025 to January 31, 2027. The goal is to delineate the independent and interactive effects of OSA and HIV on QT variability...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports a comprehensive sleep neuroimaging study to investigate the role of local sleep disturbance in obesity risk. The $568,125 award to Brigham Young University, with a period of performance from September 2025 to August 2028, will utilize advanced functional neuroimaging and polysomnographic methods to elucidate the underlying mechanisms linking poor...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $644,687 to the University of Missouri System to conduct research on a neural circuit in the brain that contributes to hypertension associated with obstructive sleep apnea. The research aims to determine how this "orexin-CRH-NTS" circuit facilitates the peripheral chemoreflex and leads to sympathoexcitation and hypertension,...
- This federal Project Grant award, valued at $755,257.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award aims to study the role of GPI-anchor biosynthesis in regulating sleep, with the goal of improving understanding of the genetic factors underlying sleep disorders such as insomnia. The research will be conducted by Texas A&M University and will involve a multi-pronged approach, including...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $816,472 project grant to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on August 1, 2025 and set to conclude on May 31, 2029, aims to enhance cardiovascular risk prediction and treatment response in obstructive sleep apnea (OSA) patients using advanced AI-based transformer models and multi-modal sleep data. The project will...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $248,088 to the University of California, San Diego (UCSD) to conduct a mechanistic study on cardiovascular outcomes in patients with comorbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), referred to as overlap syndrome (OVS). The central hypothesis is that poor cardiovascular outcomes in OVS, compared to COPD or OSA alone,...
This $782,473 federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to improve understanding of the pathogenesis of sleep apnea using novel imaging techniques during sleep. The project aims to characterize the site and pattern of airway collapse as well as how upper airway anatomy mediates this collapse, which could provide new insights to guide optimal therapies, particularly for patients who cannot tolerate positive airway pressure therapy. The research will combine state-dependent magnetic resonance imaging (MRI) and phenotyping from drug-induced sleep endoscopy to develop a better mechanistic understanding of upper airway dynamics during sleep apnea episodes. The award was granted to the University of Pennsylvania, a prominent private research university and academic medical center, and is expected to be completed by July 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $782.5k | 9/5/25 |